Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal D Shore

Showing results (121-130 of 312) with videos related to

Pageof 32
Sort By:
JCO Precision Oncology|April 18, 2024
Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide in Men Undergoing Active SurveillanceAshley E Ross, Kenneth K Iwata, Dina Elsouda, et al.
The Canadian Journal of Urology|December 22, 2015
Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancerE David Crawford, Daniel P Petrylak, Celestia S Higano, et al.
Prostate Cancer|January 7, 2026
Cellular Immunotherapy for Prostate Cancer: Lessons Learned From 15 Years of Sipuleucel-TNeal D Shore, Emmanuel S Antonarakis, Jason Hafron, et al.
European Urology|August 8, 2016
Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical TrialAxel Heidenreich, Simon Chowdhury, Laurence Klotz, et al.
Clinical Genitourinary Cancer|August 10, 2021
Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US StudyNeal D Shore, Raluca Ionescu-Ittu, François Laliberté, et al.
Journal of Medical Economics|July 15, 2025
Healthcare resource utilization and costs among patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide in the United States (2019-2023)Mehmet A Bilen, Benjamin Lowentritt, Sabree Burbage, et al.
European Urology|October 4, 2020
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer MonitoringFred Saad, Cora N Sternberg, Eleni Efstathiou, et al.
Advances in Therapy|September 15, 2023
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate CancerNeal D Shore, Bryan A Mehlhaff, Michael S Cookson, et al.
Cancer|February 8, 2017
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxelAndrew J Armstrong, Fred Saad, De Phung, et al.
BJU International|November 17, 2009
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III studyFritz H Schröder, Bertrand Tombal, Kurt Miller, et al.
Pageof 32

Showing results (121-130 of 312) with videos related to

Sort By:
Pageof 32
JCO Precision Oncology|April 18, 2024
Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide in Men Undergoing Active SurveillanceAshley E Ross, Kenneth K Iwata, Dina Elsouda, et al.
The Canadian Journal of Urology|December 22, 2015
Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancerE David Crawford, Daniel P Petrylak, Celestia S Higano, et al.
Prostate Cancer|January 7, 2026
Cellular Immunotherapy for Prostate Cancer: Lessons Learned From 15 Years of Sipuleucel-TNeal D Shore, Emmanuel S Antonarakis, Jason Hafron, et al.
European Urology|August 8, 2016
Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical TrialAxel Heidenreich, Simon Chowdhury, Laurence Klotz, et al.
Clinical Genitourinary Cancer|August 10, 2021
Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US StudyNeal D Shore, Raluca Ionescu-Ittu, François Laliberté, et al.
Journal of Medical Economics|July 15, 2025
Healthcare resource utilization and costs among patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide in the United States (2019-2023)Mehmet A Bilen, Benjamin Lowentritt, Sabree Burbage, et al.
European Urology|October 4, 2020
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer MonitoringFred Saad, Cora N Sternberg, Eleni Efstathiou, et al.
Advances in Therapy|September 15, 2023
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate CancerNeal D Shore, Bryan A Mehlhaff, Michael S Cookson, et al.
Cancer|February 8, 2017
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxelAndrew J Armstrong, Fred Saad, De Phung, et al.
BJU International|November 17, 2009
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III studyFritz H Schröder, Bertrand Tombal, Kurt Miller, et al.
Pageof 32